AstraZeneca Results Presentation Deck
2022 Guidance
Continuing to drive innovation and growth
Total revenue guidance
$Bn
45
40
35
30
25
20
15
10
5
0
Grow by high-teens %
-2%
2018
+13%
+10%
+38%
2019 2020 2021 2022E
14 Growth rates at CER.
2022 guidance range
Grow by mid-to-high twenties %
8
7
6
5
4
3
2
1
Core EPS guidance
0
-19% +0%
||
2018
2019
+18%
2020
+37%
2021 2022E
Headwinds
Ongoing pricing pressure in China,
mid single-digit revenue decline
anticipated
COVID-19 still impacting diagnosis
and treatment rates, particularly in
Oncology
Decline in COVID-19 therapies
revenue expected in 2022
Intensified competition for some
legacy medicines
Continued pricing pressure in many
markets
Tailwinds
First full year of Alexion ownership
Strong ex-China Emerging markets
growth
Continued strong uptake for key
medicines e.g. Farxiga, Tagrisso,
Calquence and Enhertu
Unique opportunity for Evusheld
to provide protection against
COVID-19 in vulnerable patients
Growth supported by a diversified business model across key disease areas and geographiesView entire presentation